Immunotherapy breakthrough: Pembrolizumab extends time to recurrence in aggressive bladder cancer Post author: Post published:January 27, 2024 Post category:uncategorized Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have a new treatment option. You Might Also Like Many young patients choose TAVR despite better long-term survival with surgery January 29, 2024 Exploring endogenous retroviruses as hidden drivers of alcohol use disorder November 7, 2025 Rising asthma rates in sub-Saharan Africa linked to urbanization and lack of care October 21, 2024